Biomarin Pharmaceutical INC Form 4 insider transactions

Henry J. Fuchs, President of Worldwide R&D at BioMarin Pharmaceutical Inc., reports transactions involving the company's common stock, including acquisitions through the Employee Stock Purchase Plan and disposals to cover tax obligations.

Erin Burkhart, GVP, Chief Accounting Officer of BioMarin Pharmaceutical Inc., sold 714 shares of common stock at $90 per share on August 13, 2024, under a pre-arranged 10b5-1 trading plan.

Brian Mueller, EVP and CFO of BioMarin Pharmaceutical Inc., disposed of 588 shares of common stock on June 28, 2024, to cover tax obligations.

Director Elaine Heron reported the acquisition and disposal of BioMarin Pharmaceutical Inc. (BMRN) common stock on June 3, 2024, according to a Form 4 filing with the SEC.

Director Richard A. Meier exercised stock options and disposed of shares of BioMarin Pharmaceutical Inc. on June 3, 2024.

Brian Mueller, EVP and CFO of BioMarin Pharmaceutical Inc., reports acquisition and disposal of company stock, including transactions under a 10b5-1 plan and the Employee Stock Purchase Plan.

EVP and Chief Legal Officer of BioMarin Pharmaceutical, George Eric Davis, exercised stock options and sold shares on May 28, 2024, under a pre-arranged 10b5-1 trading plan.

Director David E.I. Pyott reports the acquisition of 4,720 restricted stock units in BioMarin Pharmaceutical Inc.

Director Richard A. Meier reported the acquisition of 7,080 shares of BioMarin Pharmaceutical Inc. common stock on May 21, 2024, through restricted stock units.

Director Robert J. Hombach reported acquiring 4,720 shares of BioMarin Pharmaceutical Inc. common stock on May 21, 2024.

Director Maykin Ho reported the acquisition of 4,720 shares of BioMarin Pharmaceutical Inc. common stock and the disposal of 21,360 shares on May 21, 2024.

Director Elaine J. Heron reported acquiring 4,720 shares of BioMarin Pharmaceutical Inc. common stock on May 21, 2024, and now beneficially owns 96,841 shares.

Director Mark J Enyedy reports acquisition and disposal of BioMarin Pharmaceutical Inc. shares on May 21, 2024, according to a Form 4 filing.

Director Willard H. Dere reports acquisition of 4,720 restricted stock units in BioMarin Pharmaceutical Inc.

Athena Countouriotis, a director at BioMarin Pharmaceutical Inc., reported the acquisition of 4,720 restricted stock units on May 21, 2024.

Director Barbara Bodem reported the acquisition of 4,720 shares of BioMarin Pharmaceutical Inc. stock through restricted stock units and the disposal of 6,900 shares.

Director Elizabeth Anderson reports the acquisition of 4,720 restricted stock units in BioMarin Pharmaceutical Inc.

Cristin Hubbard, EVP and Chief Commercial Officer of BioMarin Pharmaceutical Inc., reports the acquisition of restricted stock units and stock options.

Director Jean Jacques Bienaime reports disposition of BioMarin Pharmaceutical Inc. shares to cover tax obligations.

Erin Burkhart, GVP, Chief Accounting Officer of BioMarin Pharmaceutical Inc., reports disposing of 993 shares of common stock to cover tax obligations.

BioMarin's CEO, Jean-Jacques Bienaime, exercised stock options and sold 40,000 shares of common stock on May 9th and 10th, 2024, under a pre-arranged 10b5-1 trading plan.

EVP, Chief Technical Officer of BioMarin Pharmaceutical Inc., Charles Greg Guyer, reports acquisition of shares through the Employee Stock Purchase Plan and disposition of shares for tax purposes.

Executive Vice President and Chief Legal Officer of BioMarin Pharmaceutical, George Eric Davis, reports acquisition and disposal of company stock, including transactions under a 10b5-1 plan and the Employee Stock Purchase Plan.

EVP, Chief Commercial Officer of BioMarin Pharmaceutical Inc., Jeffrey Robert Ajer, reports acquisition of shares through the Employee Stock Purchase Plan and disposition of shares via a pre-arranged 10b5-1 trading plan.

Director Jean Jacques Bienaime of BioMarin Pharmaceutical Inc. exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Erin Burkhart, GVP and Chief Accounting Officer of BioMarin Pharmaceutical Inc., sold 2,286 shares of common stock at $90 per share on April 10, 2024, under a pre-arranged 10b5-1 trading plan.

BioMarin's EVP, Chief Legal Officer, George Eric Davis, sold 24,602 shares of common stock at $88.34 per share on March 28, 2024, under a pre-arranged 10b5-1 trading plan.

Director Dennis Slamon exercised stock options and disposed of shares of BioMarin Pharmaceutical Inc. on March 18, 2024.

Erin Burkhart, GVP, Chief Accounting Officer of BioMarin Pharmaceutical Inc., reports the acquisition of restricted stock units and stock options, as well as the disposition of shares to cover tax obligations.

EVP, Chief Legal Officer of BioMarin Pharmaceutical Inc., George Eric Davis, reports acquisition of stock options and restricted stock units, as well as disposition of shares to cover tax obligations.